1048sek
-2,4 %
Date:2024-03-28Time:12:59:57Latest report:Q2-2024List:First NorthTicker:DMYD B
Market Cap:995 msekEnterprise Value:858 msekNet Sales:0,28 msekEarnings:-104,3 msekEmployees:0ISIN:SE0005162880

Ratios

10-year key figure history for Diamyd Medical turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Diamyd Medical with index and moving average MA50 and MA200.

Stockprice:10,48
MA50:11,55
MA200:9,14
Price/MA200:14,7 %
RSI (14):40,3
Price/MA50:-9,3 %

Description

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Biotechnology